S4

VOLUTRIP (tablet)

Dolutegravir, lamivudine and tenofovir disoproxil fumarate.

Read all of this leaflet carefully before you start taking VOLUTRIP.

- Keep this leaflet. You may need to read it again.

- If you have further questions, please ask your doctor or your pharmacist.

- VOLUTRIP has been prescribed for you personally and you should not share your

medicine with other people. It may harm them, even if their symptoms are the same as

1. WHAT VOLUTRIP CONTAINS

The active substances are dolutegravir, lamivudine and tenofovir disoproxil fumarate.

Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg of dolutegravir,

lamivudine 300 mg and tenofovir disoproxil fumarate 300 mg which is equivalent to 245 mg

of tenofovir disoproxil.

The other ingredients of VOLUTRIP are colloidal silicon dioxide, croscarmellose sodium,

ferric oxide, hypromellose, magnesium stearate, microcrystalline cellulose, opadry II pink

85F94172, povidone, sodium starch glycolate and sodium stearyl fumarate.

In addition opadry II pink 85F94172 contains iron oxide red (C.I. No: 77491), oxide black (C.I.

No: 77499), poly ethylene glycol, talc and titanium dioxide (C.I. No: 77891).

Contains sugar: 145,37 mg mannitol.

WARNING

LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, INCLUDING

FATAL CASES, HAVE BEEN REPORTED WITH THE USE OF NUCLEOSIDE

ANALOGUES ALONE OR IN COMBINATION WITH OTHER ANTIRETROVIRALS.

VOLUTRIP IS NOT INDICATED FOR THE TREATMENT OF CHRONIC HEPATITIS B

VIRUS (HBV) INFECTION. THE SAFETY AND EFFICACY OF VOLUTRIP HAS NOT BEEN

ESTABLISHED IN PATIENTS CO-INFECTED WITH HBV AND HIV. SEVERE ACUTE

EXACERBATIONS OF HEPATITIS B HAVE BEEN REPORTED IN PATIENTS WHO ARE CO-INFECTED WITH HBV AND HIV AND HAVE DISCONTINUED THE COMBINATION TABLET. HEPATIC FUNCTION SHOULD BE MONITORED CLOSELY WITH BOTH CLINICAL AND LABORATORY FOLLOW-UP FOR AT LEAST SEVERAL MONTHS IN PATIENTS WHO DISCONTINUE VOLUTRIP AND ARE CO-INFECTED WITH HIV AND HBV. IF APPROPRIATE, INITIATION OF ANTI-HEPATITIS B THERAPY MAY BE WARRANTED.

2. WHAT VOLUTRIP IS USED FOR

VOLUTRIP is a triple combination therapy used to treat human immunodeficiency virus (HIV) infection in adults aged 18 years and older.

3. BEFORE YOU TAKE VOLUTRIP

Do not take VOLUTRIP:

- If you are hypersensitive (allergic) to dolutegravir, lamivudine or tenofovir or any of the other ingredients of VOLUTRIP.
- If you suffer from uncontrolled kidney failure.
- If you are taking anti-arrhythmic medicines called dofetilide or pilsicainide.
- If you are taking a medicine called metformin which is used for lowering of blood sugar levels.
- If you are taking the antiretroviral medicine called didanosine.
- If you are taking a medicine called adefovir dipivoxil which is used to treat hepatitis B.
- If you have any liver disease (moderate or severe).
- If you are younger than 18 years old.
- If you are pregnant or planning to become pregnant or breastfeeding (see Pregnancy and Breastfeeding).

Take special care with VOLUTRIP:

- If you suffer from high cholesterol, increased blood sugar levels, insulin resistance or increased blood lactate levels, as it may worsen if you are taking VOLUTRIP.
- If you notice a redistribution/accumulation of fat, obesity, peripheral wasting, facial
 wasting and breast enlargement, inform your doctor as triple combination antiretroviral
 therapy often causes this.
- If you get any other symptoms of other serious infections as sometimes you may
 experience an inflammatory reaction that causes an existing infection to get worse. This
 is caused by the body's immune system becoming stronger.
- If you experience joint aches and pain, joint stiffness or difficulty moving or bone fractures tell your doctor as you may need to take calcium and vitamin D supplements to prevent further damage to your bones that may be caused by VOLUTRIP, when taken together with corticosteroids or alcohol, or if you have a very weak immune system and are overweight.
- As it does not prevent your risk of transmitting HIV to others through sexual contact or blood contamination. You should still take appropriate precautions.
- If you experience nausea, vomiting, abdominal pain, generalised weakness, anorexia, and sudden unexplained weight loss, and difficulty breathing you should tell your doctor immediately as you may be experiencing lactic acidosis. This usually occurs after a few months of treatment with VOLUTRIP.
- If you experience any symptoms of anaemia such as extreme tiredness or paler skin than
 usual, or if you start experiencing fits, a change in your muscle tone or unusual behaviour
 from yourself you may be experiencing mitochondrial dysfunction and should therefore
 inform your doctor immediately.
- If you experience severe abdominal pain, nausea or vomiting you need to tell your doctor immediately as he may have to do blood tests to confirm if you are suffering from inflammation of your pancreas.
- If you suffer from kidney problems you should inform your doctor, as you may not be able
 to take VOLUTRIP since the dosage cannot be adjusted.

- If you are already suffering from any liver disease you should inform your doctor as your condition may worsen while taking VOLUTRIP.
- You should tell your doctor of any medicines that you are taking or have recently taken
 as some medicines cannot be taken with VOLUTRIP as it may damage your kidneys.
- If you suffer from chronic hepatitis B or C you should tell your doctor as you should not
 be taking VOLUTRIP as it could cause severe liver damage which could even result in
 death.
- If you experience an allergic reaction with symptoms such as a severe rash, fever, general weakness and tiredness, muscle or joint aches, blisters, sores in your mouth, swelling of your face or severe abdominal pain you should stop taking VOLUTRIP immediately.

Taking VOLUTRIP with food and drink:

VOLUTRIP can be taken with or without food.

Pregnancy and breastfeeding:

- Do not take VOLUTRIP tablets if you are pregnant or breastfeeding (see Do not take
 VOLUTRIP tablets). VOLUTRIP could seriously harm your unborn child if you fall
 pregnant while on treatment or if you start taking VOLUTRIP in the first few weeks of
 your pregnancy.
- If you are pregnant or breastfeeding your baby, please consult your healthcare professional for advice before taking VOLUTRIP. You should ensure that you always use effective contraception while you are taking VOLUTRIP. Your healthcare professional can advise you on which contraceptives to take. Never stop taking VOLUTRIP without first consulting your healthcare professional as your HIV condition may become worse.
- If you are thinking of having a baby, do not stop using VOLUTRIP and contraception
 before you have talked to your healthcare professional. If you think you are pregnant go
 to your healthcare professional to get a pregnancy test and to be advised on your future
 HIV treatment and on a pregnancy management plan.

If you are pregnant or breastfeeding your baby, please consult your doctor, pharmacist or other healthcare professional for advice before taking **VOLUTRIP**.

Driving and using machinery:

You should consider the possible side effects of **VOLUTRIP** before you drive or operate machinery. You should first establish the effects of this medicine on you before driving or operating any machinery.

Important information about some of the ingredients of VOLUTRIP:

VOLUTRIP contains a type of sugar called mannitol which may have a laxative effect.

Taking other medicines with VOLUTRIP:

Always tell your healthcare professional if you are taking any other medicine. (This includes complementary or traditional medicines).

VOLUTRIP may have an effect on other medicines or other medicines may have an effect on **VOLUTRIP**.

- Lamivudine which is contained in VOLUTRIP may reduce the antiviral action of zalcitabine therefore the two medicines should not be used together.
- The antibiotic co-trimoxazole causes an increase in the level of lamivudine which is contained in VOLUTRIP in your blood.
- The following medicines will decrease the effect of **VOLUTRIP** by interacting with either of the medicines contained in the triple combination tablet: rifampicin (used in TB treatment); etravirine, efavirenz, nevirapine, tipranavir/ritonavir, fosamprenavir/ritonavir, darunavir/ritonavir (used in HIV treatment), oxcarbazepine, phenytoin, phenobarbitone, carbamazepine, St. John's wort (used for treatment of fits and depression); antacids which contain magnesium, aluminium or calcium; iron and calcium supplements.
- The following medicines will increase the effect of VOLUTRIP by interacting with either
 of the medicines contained in the triple combination tablet: Atazanavir and indinavir,
 lopinavir/ritonavir (used in HIV treatment)

 VOLUTRIP will either increase or decrease the blood levels of the following medicines if taken together: Abacavir, indinavir, atazanavir, zalcitabine (used in HIV treatment); dofetilide or pilsicainide (used to treat irregular heartbeats); and metformin used in treatment of diabetes

4. HOW TO TAKE VOLUTRIP

Do not share medicines prescribed for you with any other person.

VOLUTRIP therapy should be initiated by a medical practitioner experienced in the management of HIV infection.

Always take **VOLUTRIP** exactly as your doctor has instructed you. You should check with your doctor or pharmacist if you are unsure.

The usual dose of **VOLUTRIP** is one tablet daily and is only recommended for adults 18 years and older.

Your doctor will tell you how long your treatment with **VOLUTRIP** will last. Do not stop treatment early because this may worsen your condition and make your body resistant to the medicine. If you have the impression that the effect of **VOLUTRIP** is too strong or too weak, tell your doctor or pharmacist.

If you take more VOLUTRIP then you should:

There is no specific treatment for **VOLUTRIP** overdose therefore if you have taken more **VOLUTRIP** than you should have your doctor will treat you for the symptoms that you have.

In the event of overdosage, consult your doctor or pharmacist. If neither is available, contact the nearest hospital or poison control centre.

If you forget to take VOLUTRIP:

If you forget to take a dose, take it as soon as you remember unless it is nearly time for your next dose. Do not take a double dose to make up for forgotten individual doses.

5. POSSIBILE SIDE EFFECTS

VOLUTRIP can have side effects.

Not all side effects reported for **VOLUTRIP** are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking this medicine, please consult your doctor, pharmacist or other healthcare professional for advice.

If any of the following happens, stop taking **VOLUTRIP** and tell your doctor immediately or go to the casualty department at your nearest hospital:

- swelling of the hands, feet, ankles, face, lips, mouth or throat, which may cause difficulty in swallowing or breathing,
- rash or itching with blisters

These are all very serious side effects. If you have them, you may have had a serious allergic reaction to **VOLUTRIP**. You may need urgent medical attention or hospitalisation.

Tell your doctor immediately or go to the casualty department at your nearest hospital if you notice any of the following which may occur frequently:

- Severe upper abdominal pain
- Yellowing of your skin, white of eyes, and nails

These are all serious side effects. You may need urgent medical attention.

Tell your doctor if you notice any of the following which may occur frequently:

- Difficulty sleeping
- Headache
- Dizziness
- Abnormal dreams
- Diarrhoea
- Nausea
- Rash
- Itchy skin
- Tiredness
- Excess production of milk

- Increased blood sugar levels
- Feeling depressed
- Hair loss
- Painful muscles and joints
- Stomach cramps

The following side effects occur less frequently:

- Vomiting
- Flatulence
- A redistribution of your body fat around your body
- Pins and needles in hands and feet
- Nose and throat infections
- Nasal discharge and congestion
- Loss of appetite

The following side effects frequency unknown:

- Cough
- Wheezing chest

If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

6. STORING AND DISPOSING OF VOLUTRIP:

Store at or below 30 °C.

Keep the desiccant sachet in the container. Do not remove the desiccant sachet. Keep the tablets in the original container.

Keep HDPE containers tightly closed.

STORE OUT OF REACH AND SIGHT OF CHILDREN.

Return all unused medicine to your pharmacist.

Do not dispose of unused medicine in drains or sewerage systems (e.g. toilets).

7. PRESENTATION OF VOLUTRIP

Tablets are packed in white opaque round 100 ml HDPE container of 38 mm neck finish closed with white opaque polypropylene 38 mm- 400 child resistance closure with wad having induction sealing liner. The HDPE container also contains 3 g of silica gel sachet

Each container contains 30 tablets.

Pack size: 30's - One HDPE container contains 30 tablets.

8. IDENTIFICATION OF VOLUTRIP

Pink coloured, oval, biconvex, film coated tablet debossed with 'N33' on one side and plain on the other side.

9. REGISTRATION NUMBER

52/20.2.8/0212.210

10. NAME AND ADDRESS OF REGISTRATION HOLDER

Aurobindo Pharma (Pty) Ltd

Woodhill Office Park, Building 1

53 Phillip Engelbrecht Avenue

Meyersdal, Ext. 12, 1448

Johannesburg

South Africa

11. DATE OF PUBLICATION

31 August 2018